You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

270 Results
Document
May 2019
Document
May 2019
Document
May 2019
Document
May 2019
Document
May 2019
Document
Jul 2019
Guidelines and Advice
Status: Current
ID: PET 2018-2
Jul 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    lorlatinib - For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lorlatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Blog post
In any given year, one in five Canadians will suffer from a mental health problem. For people living with cancer and their families, the risk is...
Aug 2019
Document
Sep 2019

Pages